PFBT
CLDX icon

Parkside Financial Bank & Trust’s Celldex Therapeutics CLDX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62K Hold
51
– – ﹤0.01% 2195
2025
Q4 		$1.39K Hold
51
– – ﹤0.01% 2227
2025
Q3 		$1.32K Buy
51
+26
+104% +$602 ﹤0.01% 2172
2025
Q2 		$510 Sell
25
-15
-38% -$292 ﹤0.01% 2539
2025
Q1 		$726 Buy
+40
New +$894 ﹤0.01% 2210

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Parkside Financial Bank & Trust's CLDX Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 51 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

Parkside Financial Bank & Trust first reported a position in CLDX in Q1 2025 and has held it in 5 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Parkside Financial Bank & Trust held 51 shares of Celldex Therapeutics worth $1.62K as of Q1 2026.
  • Parkside Financial Bank & Trust left its Celldex Therapeutics share count unchanged in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2195 holding.
  • Parkside Financial Bank & Trust first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.